U.S. Food and Drug Administration Issues Emergency Use Authorization for KINERET® (anakinra) for the Treatment of COVID-19-Related Pneumonia

Early treatment with KINERET reduced disease progression by 64 percent in hospitalized COVID-19 patientsi WALTHAM, Mass., Nov. 10, 2022 -- Sobi North America, the North American affiliate of... | November 10, 2022

Related Keywords

Waltham ,Massachusetts ,United States ,Italy ,Stockholm ,Sweden ,Boston ,Toronto ,Ontario ,Canada ,Greece ,America ,Canadian ,American ,John Yee ,Linkedin ,Twitter ,Hellenic Institute For The Study Of Sepsis ,World Health Organization ,Drug Administration ,Globenewswire Inc ,North America ,North American ,Coronavirus Disease ,Nature Medicine ,Chief Medical Officer ,Cosmetic Act ,For Sobi ,Guided Anakinra Treatment ,Severe Respiratory Failure ,Health Organization ,Cryopyrin Associated Periodic Syndromes ,Neonatal Onset Multisystem Inflammatory Disease ,Tumor Necrosis Factor ,Nat Med ,Swedish Orphan Biovitrum Ab Publ Stock Exchange ,News ,Information ,Press Release ,Early ,Treatment ,Ith ,Kineret ,Educed ,Disease ,Progression ,Y ,4 ,Ercent ,N ,Hospitalized ,Atientsi ,022 ,Gobi ,North ,The ,Ffiliate Sobi Se0000872095 ,